LAS VEGAS – The TearScience LipiScan, which was launched in May, has been well received among eye care providers, according to company executives. They also shared recent study results with Primary Care Optometry News here at Vision Expo West.
According to TearScience President and CEO Joseph Boorady, OD, clinical study results involving 404 eyes of 200 patients showed that a single treatment with the LipiFlow can sustain improvement in meibomian gland function and reduction in dry eye symptoms over 12 months.
“The whole group had a 50% reduction in symptoms and tripled the gland scores, sustained over 12 months,” he told PCON.
The earlier the patients were treated in the disease, the better the outcomes, Brian Regan, TearScience vice president of marketing and market development, added.
The LipiFlow measures tear film and blink quality and provides dynamic meibomian imaging. The recently released LipiScan provides high-definition meibomian imaging. – by Nancy Hemphill, ELS, FAAO